Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Davendra P. S. Sohal

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0182-8403; OpenAlex author ID A5065605420; NIH RePORTER profile ID 11640542. Sources: OpenAlex.

Their work

Papers
37 (first author 2, last author 0)
Trials
0
Grants
2
Labs led
1
Collaborators
172
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 4 papers · 2018: 4 papers · 2019: 3 papers · 2020: 4 papers · 2021: 1 paper · 2022: 4 papers · 2023: 2 papers · 2024: 6 papers, 1 grant · 2025: 1 paper · 2026: 3 papers, 1 grant

Papers 37

  1. Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreat… Co-author DOI 10.1200/jco-25-02199↗
  2. Assessing Response and Outcomes to Modern Multiagent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-19990-7↗
  3. ASO Visual Abstract: Assessing Response and Outcomes to Modern Multi-Agent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20039-y↗
  4. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  5. Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational s… Co-author DOI 10.1016/j.esmogo.2024.100042↗
  6. Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma - analysis from SWOG S1505. Co-author DOI 10.1016/j.gassur.2023.12.022↗
  7. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2024.01.013↗
  8. First-in-Class Humanized Antibody against Alternatively Spliced Tissue Factor Augments Anti-Metastatic Efficacy of Chemotherapy in a Preclinical Model of Pancr… Co-author DOI 10.3390/ijms25052580↗
  9. Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. Co-author DOI 10.3390/ijms25169041↗
  10. Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505. Co-author DOI 10.6004/jnccn.2023.7099↗
  11. Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101013↗
  12. Pancreatic Adenocarcinoma Management. First author DOI 10.1200/op.22.00328↗
  13. Radiation therapy in borderline resectable pancreatic cancer: A review. Co-author DOI 10.1016/j.surg.2021.12.013↗
  14. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-3581↗
  15. Systemic Therapy for Resected Pancreatic Adenocarcinoma: How Much is Enough? Co-author DOI 10.1245/s10434-022-11363-0↗
  16. Is There a Benefit to Adjuvant Chemotherapy in Resected, Early Stage Pancreatic Ductal Adenocarcinoma? Co-author DOI 10.1245/s10434-022-11580-7↗
  17. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2020.7328↗
  18. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor … Co-author DOI 10.1016/s1470-2045(20)30074-7↗
  19. Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectabl… Co-author DOI 10.1097/sla.0000000000004155↗
  20. Metastatic Pancreatic Cancer: ASCO Guideline Update. Co-author DOI 10.1200/jco.20.01364↗
  21. A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic c… Co-author PMID 33042633↗
  22. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Co-author DOI 10.1002/cam4.2425↗
  23. Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program. Co-author DOI 10.1200/po.19.00115↗
  24. Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. Co-author DOI 10.7554/elife.50663↗
  25. Adjuvant Treatment in Potentially Curable Pancreatic Cancer: Need to Include Tumor Location in the Equation? First author DOI 10.1097/mpa.0000000000001125↗
  26. Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. Co-author DOI 10.1158/1078-0432.ccr-18-0531↗
  27. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. Co-author DOI 10.1200/jco.2018.78.9636↗
  28. Point: Weighing the Risks and Benefits of Neoadjuvant Therapy in Resectable Pancreatic Cancer. Early, Aggressive Neoadjuvant Therapy Is Appropriate in Selected… Co-author PMID 29447420↗
  29. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. Co-author DOI 10.1186/s12957-017-1240-2↗
  30. Pancreatic Adenocarcinoma: Improving Prevention and Survivorship. Co-author DOI 10.1200/edbk_175222↗
  31. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. Co-author DOI 10.1200/jop.2016.017368↗
  32. Adjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma. Co-author DOI 10.21037/cco.2017.06.23↗
  33. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Co-author DOI 10.1200/jco.2016.67.1412↗
  34. Predicting early mortality in resectable pancreatic adenocarcinoma: A cohort study. Co-author DOI 10.1002/cncr.29298↗
  35. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. Co-author DOI 10.1093/jnci/dju011↗
  36. Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally a… Co-author DOI 10.1007/s00280-013-2147-4↗
  37. Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenocarcinoma. Co-author DOI 10.6092/1590-8577/449↗

Grants 2

  1. NCI-Sponsored Leadership Focused on Clinical Trial Enrollment R50CA305011↗
  2. Phase I/II clinical evaluation of ABTL0812, a novel PI3K/Akt/mTOR inhibitor, with a unique mechanism of action inpancreatic cancer (Protocol sent on 20th June … R01FD006817↗

Closest collaborators

The 25 strongest of 172 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Syed Ameen Ahmad · 6 shared papers, 2021–2024 · strength 0.98
  2. Jordan R. Kharofa · 5 shared papers, 2022–2026 · strength 0.97
  3. Gregory C. Wilson · 5 shared papers, 2022–2026 · strength 0.97
  4. Olugbenga Olanrele Olowokure · 5 shared papers, 2022–2026 · strength 0.97
  5. Sameer H. Patel · 5 shared papers, 2022–2026 · strength 0.97
  6. Philip A. Philip · 8 shared papers, 2016–2024 · strength 0.90
  7. Elena Gabriela Chiorean · 5 shared papers, 2020–2024 · strength 0.81
  8. Andrew Eugene Hendifar · 6 shared papers, 2018–2026 · strength 0.69
  9. Andrea Wang‐Gillam · 5 shared papers, 2019–2024 · strength 0.65
  10. Alok A. Khorana · 7 shared papers, 2014–2025 · strength 0.61
  11. Muhammad Shaalan Beg · 4 shared papers, 2020–2024 · strength 0.58
  12. Andrew M. Lowy · 4 shared papers, 2020–2024 · strength 0.58
  13. Jordan M. Cloyd · 3 shared papers, 2024–2025 · strength 0.54
  14. Ryan P. Johnson · 2 shared papers, 2026 · strength 0.53
  15. Syed A. Ahmad · 2 shared papers, 2026 · strength 0.53
  16. Paul H. McClelland · 2 shared papers, 2026 · strength 0.53
  17. Eileen Mary O'Reilly · 6 shared papers, 2016–2025 · strength 0.50
  18. Kevin M. Turner · 3 shared papers, 2022 · strength 0.44
  19. Vincent M. Chung · 4 shared papers, 2018–2025 · strength 0.39
  20. Yan Jiang · 1 shared paper, 2023 · strength 0.39
  21. Vivek U. Nimgaonkar · 2 shared papers, 2023–2026 · strength 0.33
  22. Eric Andrew Collisson · 2 shared papers, 2023–2026 · strength 0.33
  23. Christos K Fountzilas · 2 shared papers, 2023–2026 · strength 0.33
  24. Aatur Dilip Singhi · 2 shared papers, 2023–2026 · strength 0.33
  25. Ignacio Garrido‐Laguna · 3 shared papers, 2018–2024 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.